Decision Support · Side-by-side
Compare pricing, strengths, and use cases so it is easier to pick the right fit.
Change tools
Neither Arctoris nor Entos is for everyday users—both are specialized enterprise platforms for drug discovery. Arctoris wins if you need automated, reproducible wet-lab experiments; Entos wins if you need high-accuracy computational molecular prediction. The single biggest difference: Arctoris runs physical robots, Entos runs quantum-accurate simulations.
Arctoris
Entos
Scores at a glance
Choose Arctoris if
Choose Entos if
Key differences
Facts side by side
| Arctoris | Entos | |
|---|---|---|
| Free plan | ||
| Mobile app | ||
| API access |
Common questions
No. Neither tool has a mobile app. Both are designed for desktop or server use by trained scientists.
Neither is easy for beginners. Entos has a slightly lower barrier if you already know computational chemistry, but both require expert-level onboarding and significant upfront setup.
It depends on your stage. Arctoris is better if you need real experimental data from robots. Entos is better if you want to predict properties computationally before making anything in the lab.
Neither publishes pricing. Both are enterprise-grade platforms, so expect costs in the tens to hundreds of thousands of dollars per year. They are not for individual researchers or small startups without funding.
Both list no integrations. Arctoris can output data in JSON/CSV for your own AI models, and Entos accepts standard chemical file formats (SMILES, SDF, PDB), but there are no plug-and-play integrations with common lab software.
Arctoris and Entos are both powerful but niche enterprise tools for drug discovery—skip them unless you're a trained scientist with a big budget.
If you're a non-technical person looking for an AI tool to use on your phone or laptop, neither Arctoris nor Entos is right for you—they're specialized platforms for professional drug discovery teams. For everyday users, consider simpler AI tools like ChatGPT or Perplexity for general tasks.
